HIV epidemic in the Maghreb. Magnitude, trend and management

##plugins.themes.academic_pro.article.main##

M. Chakroun
F. Razik
M. Karkouri
Z. Fall Malick
H. Benothman
J. George Hermez

Abstract

Over the last two decades, many progress has transformed the profile of HIV infection and improved the survival and quality of life of people living with HIV (PLHIV). In addition to individual benefits, antiretrovirals allow through viral suppression to prevent HIV transmission. The dual benefit, curative and preventive, of antiretrovirals has propel HIV testing at the forefront of the global Fast Track strategy as principle access to care and prevention. In the Maghreb countries, these achievements are impeded by a number of barriers that limit access for PLHIV, especially key populations and vulnerable populations, to appropriate care and prevention services. In order to achieve the global goals of Fast Track strategy, policy makers need to implement high-impact interventions to facilitate access to HIV testing, improve referral to care, strengthen adherence and retention to care. This can be achieved through mobile and community-based testing to target key populations, and innovative approaches such as partner notification and HIV self-testing. The establishment of robust links to care centers ensures rapid initiation of antiretrovirals in order to achieve viral suppression. Morever, these goals can be achieved by removing barriers to access to HIV testing and care. This is include specific interventions based on the respect of human rights, the fight against stigma and discrimination, the review of legislation limiting the legal age for access to voluntary testing and the removal of punitive laws against key populations.

Keywords:

Epidemic - HIV infection - Voluntary testing - Antiretrovirals - Viral suppression - North Africa

##plugins.themes.academic_pro.article.details##

References

  1. Global HIV statistics. Fact sheet. UNAIDS, July 2017.
  2. Communiqué de presse ONUSIDA. Des dirigeants mondiaux s'engagent à mettre fin à l'épidémie de sida dans les villes d'ici 2030. Melbourne, 20 juillet 2014.
  3. « 90-90-90 » Une cible ambitieuse de traitement pour aider à mettre fin à l'épidémie du sida. ONUSIDA, 2014.
  4. En finir avec le sida. Progresser vers les cibles 90-90-90. ONUSIDA.
  5. M.S. Cohen, Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016; 375:830-839
  6. Prevention gap report. UNAIDS,2016.
  7. Estimation du spectrum. ONUSIDA, 2018.
  8. Guide de dépistage de l'infection à VIH dans la région du Maghreb. Plateforme MENA, Mars 2017.
  9. Plan stratégique national de lutte contre le Sida, 2012-2016. Ministère de la Santé, Royaume du Maroc.
  10. Source : http://www.unaids.org/fr/regionscountries/countries/
  11. Plan Stratégique National de lutte contre le Sida, 2017-2021. Ministère de la Santé, Royaume du Maroc.
  12. Enquête par Grappes à Indicateurs Multiples (MICS) 2015. Office Nationale de la Statistique -Mauritanie, novembre 2016. http://www.sante.gov.mr/?wpfb_dl=197.
  13. El Moussi A, Thomson M. M, Delgado E, Cuevas M.T and al. AIDS 2016.
  14. Plan Stratégique National de lutte contre le Sida, 2016-2020. Ministère de la Santé, de la population et de la réforme Hospitalière, République Algérienne Démocratique Populaire.
  15. Plan Stratégique National de la riposte au VIH/SIDA et aux IST, 2015-2018. Ministère de la Santé, République Tunisienne.
  16. Consolidated guidelines on HIV testing services and partner notification. Supplement to guidelines on HIV testing services. WHO, december 2016.
  17. Les déterminants d'une mauvaise observance du traitement antirétroviral chez les personnes vivant avec le VIH. Revue Tunisienne d'Infectiologie 2015, 9 ; 3-4 : 79-83.
  18. Fall-Malick FZ, Tchiakpé E, Ould Soufiane S, Diop-Ndiaye H, Mouhamedoune Baye A, Ould Horma Babana A, Touré Kane C, Lo B, Mboup S. Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania. J Med Virol 2014; 86(3):404-
  19. Socías ME, Rotryng F, Lapadula P, Medrano M, Paz D, Stern L, Lambierto A, Pryluka D. Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time? J Infect Dev Ctries. 2013 Aug 15;7(8):593-9
  20. Accélérer la prévention combinée afin de réduire les nouvelles infections par le vih à moins de 500 000 d'ici à 2020. ONUSIDA, 2015.
  21. CF. Careces, KR. O'Reilly, KH. Mayer, R. Baggaley. Implementation: moving from trials to policy and practice. Journal of the International AIDS Society 2015, 18(Suppl 3): 20222. http://dx.doi.org/10.7448/IAS.18.4.20222.
  22. Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med. 2003 Jul;57(1):13-24.